About this journal
Aims and scope
Aims and scope
The International Journal of Hyperthermia is an Open Access, peer-reviewed journal publishing research and clinical studies on thermal energy-based disease treatments. It is the official journal of the Society for Thermal Medicine, the European Society for Hyperthermic Oncology, and the Japanese Society for Thermal Medicine.
The journal’s audience includes researchers and clinicians from all backgrounds as the journal publishes research related to the clinical studies, biological studies, and physics/engineering studies of therapeutic thermal therapies.
The journal has a special interest in the following topics:
• Clinical studies describing whole, regional or local treatment in humans or other animals covering the application of therapeutic thermal energy treatment alone or in combination with other clinical modalities
• Clinical outcomes on the physiological effects of heat or cold stress
• Clinical testing of methods related to thermal technologies
• Biological studies incorporating biochemical, anatomical or physiological studies of a basic or preclinical nature using basic biochemical, cell, animal, or computational models
• Research covering thermal tolerance, stress or shock, response and injury, immunological and physiological effects, toxicity and drug delivery, gene therapy, nanotechnology and nanomedicine
• The development of technologies and strategies for energy delivery and control, with an end goal to effect specific biologic responses leading to therapeutic outcomes
• Modalities and technology of therapy delivery, imaging, temperature management, and treatment monitoring and verification
• Advances in energy systems to produce tissue heating or cooling, or temperature monitoring and validation, or to control tissue temperature regulation
• Methods of measuring and modelling hypothermia and the thermal therapies and related technologies and systems
The journal welcomes for consideration the following article types: original articles, reviews, and letters to the editor. All articles received by the Journal will be subject to single-anonymous peer review.
Read the br />
Journal metrics
Usage
- 762K annual downloads/views
Citation metrics
- 3.0 (2023) Impact Factor
- Q2 Impact Factor Best Quartile
- 3.1 (2023) 5 year IF
- 5.9 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.941 (2023) SNIP
- 0.827 (2023) SJR
Speed/acceptance
- 27 days avg. from submission to first decision
- 32 days avg. from submission to first post-review decision
- 17 days avg. from acceptance to online publication
- 43% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
EDITOR-IN-CHIEF
Hans Crezee, PhD – University of Amsterdam, The Netherlands, [email protected]
EDITOR EMERITUS
M. W. Dewhirst, DVM, PhD - Duke University, Durham, NC, USA
EXECUTIVE COMMITTEE
Nahum Goldberg, MD – Beth Israel Deaconess Medical Center Boston, MA, USA
Rolf Issels, MD – Klinikum Grosshadern, Munich, Germany
Chang Song, PhD – University of Minnesota, Minneapolis, MN, USA
Paul Sugarbaker, MD – Washington Hospital Center, Washington DC, USA
Gerard van Rhoon, PhD – Erasmus University, Rotterdam, The Netherlands
SECTION EDITORS
Hyperthermia
Rudiger Wessalowski, MD – Medical University, Düsselfdorf, Germany
Thermal Ablation
Roberto Cazzato, MD, PhD – Hopitaux Universitaires de Strasbourg, France
Erik Cressman, MD, PhD – University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dimitrios Filippiadis MD, PhD - National and Kapodistrian University of Athens, Greece
Giovanni Mauri, MD – European Institute of Oncology, Milan, Italy
Hyunchul Rhim, MD – Samsung Medical Center , Seoul, Republic of Korea
Constantinos Sofocleous, MD – Memorial Sloan Kettering Cancer Center, New York, NY, USA
Timothy Ziemlewicz, MD – University of Wisconsin, Madison , Wisconsin, USA
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Wim Ceelen, MD, PhD – University of Ghent, Belgium
Guillaume Passot, MD – Hospices Civils de Lyon, France
High Intensity Focused Ultrasound (HIFU)
Jean-Francois Aubrey, PhD – CNRS, Paris, France
Gail ter Haar, PhD – Royal Marsden Hospital, Sutton, Surrey, UK
Joan Vidal-Jové, MD, PhD - Institut Khuab for Interventional Oncology, Barcelona, Spain
Vera Khokhlova, PhD – Moscow State University, Russia
Lian Zhang, MD - Chongqing Medical University, China
Engineering/Physics
Dieter Haemmerich, PhD – Medical College of South Carolina, Charleston, SC, USA
Maarten Paulides, PhD – Eindhoven University of Technology (TU/e), The Netherlands
Punit Prakash, PhD – Kansas State University, Manhattan, KS, USA
Gal Shafirstein, PhD – Roswell Park Cancer Center, Buffalo, NY, USA
Nanotechnology/Ferrofluids
Robert Ivkov, PhD – Johns Hopkins University School of Medicine, Baltimore, MD, USA
Tumor Biology
Robert Griffin, PhD – University of Arkansas Medical School, Little Rock, AR, USA
Tumor Immunology/Physiology
Elizabeth Repasky, PhD – Roswell Park Cancer Center, Buffalo, NY, USA
Heat Stress/Heat Stroke
Abderrezak Bouchama, MD - King Abdullah International Medical Research Center, Saudi Arabia
EDITORIAL BOARD
Anilchandra Attaluri, PhD – Pennsylvania State University, USA
Jung Hwan Baek, MD, PhD – Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Andris Bakuzis, PhD – Federal University of Goias, Brazil
Enrique Berjano, PhD – Universitat Politècnica de de València, Spain
Lukas Beyer, MD – University of Regensburg, Germany
Lana Bijelic, MD – Inova Fairfax Hospital , Falls Church, VA, USA
Rajiv Chopra, PhD – University of Texas Southwestern Medical Center, Dallas, TX, USA
Chris Diederich, PhD – UCSF Comprehensive Cancer Center, San Francisco, CA, USA
Rohan Fernandes, PhD – George Washington University, Washington, DC, USA
Udo Gaipl, PhD – Universitätsklinikum Erlangen, Germany
Peiman Ghanouni, MD, PhD – Stanford University Medical Center, CA, USA
Holger Gruell, PhD – University Hospital, Cologne, Germany
Mark Hurwitz, MD – New York Medical College, Valhalla, NY, USA
Brant Inman, MD – Duke University, Durham, NC, USA
Kagayaki Kuroda, PhD – Tokai University, Hiratsuka, Japan
Orlando Laitano, PhD - University of Florida, Gainesville, FL, USA
Suzanne LeBlang, MD – Focused Ultrasound Foundation, Charlottesville, VA, USA
Nicole Levi, PhD – Wake Forest University, Winston-Salem, NC, USA
Faheez Mohamed MD, FRCS – Peritoneal Malignancy Institute, Basingstoke, UK
Jason Molitoris, MD, PhD – University of Maryland, Baltimore, MD, USA
Ejung Moon, PhD - University of Oxford, Oxford, UK
Takayuki Ohguri, MD, PhD – University of Occupational & Environmental Health, Kitakyushu, Japan
Hideyuki Sakurai, MD – University of Tsukuba, Ibaraki, Japan
Paul Stauffer, MS – Thomas Jefferson Hospital, Philadelphia, PA, USA
Akihisa Takahashi, Ph.D - Gunma University Heavy Ion Medical Center, Japan
Timo ten Hagen, PhD – Erasmus Medical Center, Rotterdam, The Netherlands
Melissa Teo, MD – National Cancer Centre, Singapore
Thomas Vogel, MD - Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
Toshikazu Yoshigawa, PhD – Kyoto Prefectural University of Medicine, Japan
Jennifer Yu, MD, PhD - Cleveland Clinic, Ohio, USA
Lifei Zhu, PhD – Washington University, St. Louis, MO, USA
Abstracting and indexing
The International Journal of Hyperthermia is included in the following abstracting and indexing services:
DOAJ; EBSCO Online; Index Medicus; MEDLINE; PubMed; Scopus; Sociedad Iberoamericana de Información Científica (SIIC); Science Citation Index.
Open access
International Journal of Hyperthermia is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
Calls for papers
Society information
Continuous publication
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors